News
-
-
-
-
PRESS RELEASE
Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie
De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie. Sanofi présente ces avancées lors du 32ème Congrès de l'ISTH à Bangkok -
PRESS RELEASE
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
Sanofi presents new data on ALTUVIIIO and fitusiran at ISTH Congress, showcasing potential first- and best-in-class treatments for hemophilia. Fitusiran NDA under FDA review with PDUFA date of March 28, 2025 -
-
-
PRESS RELEASE
BEACN Closes First Tranche of Non-Brokered Private Placement
BEACN Wizardry & Magic Inc. closes First Tranche of non-brokered private placement, issuing 2,890,578 common shares for gross proceeds up to $520,304.04. Shareholders owning more than 10% participated. Proceeds to be used for sales initiatives, inventory purchases, R&D, and working capital -
-